Immunologic Factor
Johnson & Johnson’s TREMFYA Receives FDA Approval for Ulcerative Colitis, Expanding Treatment Options
TREMFYA, guselkumab, FDA approval, ulcerative colitis, inflammatory bowel disease, Johnson & Johnson
Dupixent (Dupilumab) Shows Promising Results in Treating Bullous Pemphigoid, Paving Way for Regulatory Submissions
Dupixent, Dupilumab, Bullous Pemphigoid, Autoimmune Disease, Biologic Treatment, Type 2 Inflammation
GSK’s Therapeutic Herpes Vaccine Fails to Meet Efficacy Objective in Phase I/II Trial
GSK, therapeutic herpes vaccine, herpes simplex virus, HSV, vaccine failure, clinical trial
Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients
Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)
Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease
Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development
Enhancing Flu Vaccine Manufacturing and Supply: A Comprehensive Overview
Flu Vaccine Manufacturing, Supply Chain Reliability, Influenza Vaccine Production, Vaccine Manufacturing Technologies, Pandemic Preparedness
AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms
AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study
WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%
Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.